A Urine Test Can Now Detect 80% of Canine Bladder Cancers
Scottish Terriers are 18 to 20 times more likely to develop transitional cell carcinoma (TCC) — the most common form of bladder cancer — than the average dog. Until recently, diagnosing this bladder cancer required invasive biopsy. Now, a simple free-catch urine sample can detect the BRAF V595E mutation present in approximately 80% of cases — a breakthrough that changes when and how this disease gets caught.
TCC (also called urothelial carcinoma) represents 75-90% of all urinary bladder tumors in dogs. The tumor typically develops in the trigone region — the area at the bladder neck where the ureters enter and the urethra exits — making complete surgical excision extremely difficult. Canine TCC bears remarkable biological similarity to human invasive bladder cancer, sharing histological features, molecular pathways, and drug responses (Knapp et al., 2014). This overlap means advances in canine TCC treatment directly inform human oncology, and vice versa.
The BRAF Mutation
Decker et al. (2015) made a significant discovery: the BRAF V595E mutation (homologous to the human BRAF V600E mutation found in melanoma and other human cancers) is present in approximately 80% of canine TCC cases. This finding has two major practical implications:
Non-Invasive Diagnosis
The BRAF mutation can be detected in free-catch urine samples through PCR testing. This means that dogs presenting with lower urinary tract signs (straining to urinate, blood in urine, frequent urination) can be screened for TCC with a simple urine test rather than requiring invasive bladder biopsy. The BRAF mutation test has high specificity — a positive result in a dog with compatible clinical signs and imaging is essentially diagnostic.
The limitation is sensitivity: approximately 20% of TCC cases do not carry the BRAF mutation and will test negative on urine BRAF testing. A negative BRAF result does not rule out TCC. For BRAF-negative cases, diagnosis requires cystoscopic biopsy or traumatic catheterization for cytology.
Potential Targeted Therapy
The identification of the BRAF mutation opens the door to targeted therapy with BRAF inhibitors (e.g., vemurafenib) and MEK inhibitors that have shown efficacy in BRAF-mutant human cancers. Clinical trials evaluating these targeted agents in canine TCC are ongoing but have not yet produced published outcome data sufficient for clinical recommendations.
Breed Predisposition
The breed risk distribution for TCC is striking:
- Scottish Terriers: The most dramatically predisposed breed, with an 18-20x relative risk compared to mixed breeds. Approximately 1 in 30 Scottish Terriers will develop TCC.
- Shetland Sheepdogs: Approximately 4x relative risk
- West Highland White Terriers: 3-4x relative risk
- Beagles: 3x relative risk
- Wire Fox Terriers: Elevated risk
- Airedale Terriers: Elevated risk
The overrepresentation of terrier breeds suggests a genetic susceptibility that may interact with environmental risk factors. Epidemiological studies have identified exposure to lawn chemicals (herbicides, particularly phenoxyacetic acid compounds), cyclophosphamide (a chemotherapy agent that causes sterile hemorrhagic cystitis), and possibly second-hand tobacco smoke as environmental risk factors that may interact with breed genetic susceptibility.
Clinical Presentation
The typical presenting signs are indistinguishable from lower urinary tract infection:
- Hematuria (blood in urine) — present in 50-70% of cases
- Stranguria (straining to urinate) — present in 50-60%
- Pollakiuria (frequent urination of small volumes) — present in 50-60%
- Recurrent UTI — TCC predisposes to secondary bacterial urinary tract infection, and many dogs are initially treated with multiple courses of antibiotics before the underlying tumor is identified
The diagnostic delay is significant. Dogs with TCC are often treated for “chronic UTI” or “chronic cystitis” for weeks to months before imaging reveals the bladder mass. In older dogs of predisposed breeds presenting with recurrent urinary tract signs, TCC should be on the differential list from the first presentation.
Treatment
Piroxicam
Knapp et al. (1994) published the foundational study on piroxicam for canine TCC. This NSAID with preferential COX-2 inhibitory activity produced measurable anti-tumor responses:
- Complete remission: 2%
- Partial remission: 16%
- Stable disease: 59%
- Median survival: approximately 6 months
These results established piroxicam as a cornerstone of TCC treatment. The anti-tumor mechanism involves COX-2 inhibition (COX-2 is strongly overexpressed in canine TCC), anti-angiogenic effects, and potentially enhanced immune recognition of tumor cells.
Piroxicam + Mitoxantrone
Henry et al. (2003) combined piroxicam with mitoxantrone (an anthracenedione chemotherapy agent) and demonstrated:
- Complete remission: 4%
- Partial remission: 35%
- Stable disease: 39%
- Median survival: approximately 11 months
The combination protocol remains one of the most widely used TCC treatments, offering improved response rates and survival over piroxicam alone.
Other Chemotherapy Options
- Piroxicam + chlorambucil: Oral protocol with modest response rates, used when mitoxantrone is not available or tolerated
- Piroxicam + vinblastine: Some evidence for activity; used as an alternative to mitoxantrone
- Carboplatin: Used in some rescue protocols for progression after mitoxantrone
- Metronomic cyclophosphamide + piroxicam: Low-dose continuous oral protocol with anti-angiogenic rationale
Surgery
Complete surgical excision is rarely possible due to the trigone location. Partial cystectomy may be performed for tumors in the apex or body of the bladder, but margins are frequently incomplete. Laser ablation via cystoscopy provides palliative debulking. Radical cystectomy with urinary diversion (ureteral stenting or neobladder construction) is technically feasible but rarely performed due to high complication rates and significant impact on quality of life.
Palliative Stenting
For TCC causing urethral obstruction (inability to urinate) — a common complication in advanced disease — urethral stent placement provides immediate relief and restores urine flow. Stenting is palliative and does not treat the cancer, but it can extend comfortable survival by weeks to months in dogs that would otherwise require euthanasia for urinary obstruction.
Prognosis
median survival with piroxicam-based protocols is 6-12 months from diagnosis. Factors associated with longer survival include:
- Smaller tumor volume at diagnosis
- Absence of metastasis at presentation
- Response to initial treatment (tumor shrinkage or stabilization)
- Lower mitotic index on biopsy
Metastasis occurs in approximately 20% of dogs at the time of diagnosis and in 50-60% of dogs by the time of death, most commonly to regional lymph nodes, lungs, and bone. Dogs that present with metastatic disease have median survival times under 4 months.
Screening and Early Detection
For high-risk breeds (particularly Scottish Terriers), periodic screening may enable earlier diagnosis:
- Annual urine BRAF testing starting at age 6 is a low-cost, non-invasive screening approach. A positive result warrants immediate bladder imaging.
- Abdominal ultrasound can visualize bladder masses as small as 0.5-1 cm, though sensitivity depends on mass location and ultrasonographer experience.
- Urinalysis with attention to persistent microhematuria in the absence of UTI may provide early clinical suspicion.
Whether early detection through screening improves survival is unproven but biologically plausible — smaller tumors are more likely to be amenable to partial cystectomy with clean margins, and treatment response may be better when tumor burden is lower.
Limitations
Most TCC outcome data comes from referral oncology populations, introducing selection bias toward dogs whose owners pursue treatment. The optimal sequencing and combination of available therapies has not been established through randomized controlled trials. The role of the BRAF mutation as a therapeutic target remains investigational. Environmental risk factor modification (avoiding lawn chemical exposure in predisposed breeds) is supported by epidemiological association but has not been confirmed by prospective intervention studies.
Frequently Asked Questions
What is transitional cell carcinoma in dogs?
Transitional cell carcinoma (TCC) is the most common bladder cancer in dogs, arising from the cells lining the urinary bladder. It typically develops in the trigone area (where the ureters enter the bladder), which makes complete surgical removal difficult. TCC accounts for approximately 2% of all canine cancers but is disproportionately common in certain breeds.
Which breeds are most at risk for bladder cancer?
Scottish Terriers have a 20-fold increased risk compared to mixed breeds — the highest breed predisposition of any canine cancer. Other breeds with elevated risk include Shetland Sheepdogs, Beagles, West Highland White Terriers, and Wire Fox Terriers. Female dogs are more commonly affected than males.
Can bladder cancer be detected early in dogs?
Yes. The BRAF mutation urine test can detect approximately 80% of canine transitional cell carcinomas from a simple urine sample, making it one of the most effective cancer screening tests available in veterinary medicine. For high-risk breeds, annual BRAF testing starting at age 6-8 provides an opportunity for early detection when treatment options are broadest.
What is the prognosis for dogs with bladder cancer?
Median survival with treatment (typically piroxicam or other NSAID plus mitoxantrone chemotherapy) is approximately 6-12 months. Some dogs survive longer with aggressive management. Without treatment, median survival is 4-6 months. Early detection through screening allows treatment to begin before clinical signs develop, which may improve outcomes.
Bottom Line
The BRAF mutation urine test can now detect approximately 80% of canine bladder cancers non-invasively, changing the diagnostic landscape for this disease. Scottish Terriers face 18-20 times the average risk and benefit most from periodic urine screening starting at age 6. Piroxicam combined with mitoxantrone remains the standard treatment, extending median survival to approximately 11 months, and environmental risk reduction — particularly avoiding lawn herbicide exposure — is supported by epidemiological evidence in predisposed breeds.
References
- Knapp DW et al. Naturally occurring canine transitional cell carcinoma of the urinary bladder: a relevant model of human invasive bladder cancer (Urologic Oncology, 2014).
- Decker B et al. Homologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer (Cancer Research, 2015).
- Henry CJ et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma (Clinical Cancer Research, 2003).
- Knapp DW et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder (Journal of Veterinary Internal Medicine, 1994).